We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Arecor Therapeutics Plc | LSE:AREC | London | Ordinary Share | GB00BMWLM973 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 136.50 | 133.00 | 140.00 | 136.50 | 136.50 | 136.50 | 13,750 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 3.54M | -9.26M | -0.3024 | -4.51 | 41.8M |
TIDMAREC
RNS Number : 6673A
Arecor Therapeutics PLC
23 January 2024
Arecor Therapeutics plc
("Arecor" or the "Company")
ARECOR ANNOUNCES UPDATE ON INBRX-101
- Sanofi to acquire Inhibrx's AATD therapy INBRX-101, which incorporates a novel formulation developed under a license agreement using Arecor's Arestat (TM) technology, for up to $2.2 billion
- Terms of Arecor's license agreement are unchanged. Arecor remains entitled to further payments on achievement of certain development, regulatory and commercial milestones along with annual technology access fees post commercialisation
Cambridge, UK, 23 January 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, notes the news announced today from Inhibrx, Inc. (Nasdaq: INBX) and Sanofi (Nasdaq: SNY) that the companies have entered into a definitive agreement under which Sanofi will acquire all the assets and liabilities associated with INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT") augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency ("AATD").
INBRX-101 incorporates a novel enhanced formulation developed by Arecor, using the Company's patented technology, Arestat(TM), under a license agreement entered into by Arecor and Inhibrx in December 2020. In November 2023 , Arecor announced that, under the terms of its license agreement, a milestone payment from Inhibrx had been triggered. The terms of the license agreement remain unchanged and, following the acquisition, Arecor remains entitled to further payments on the achievement of certain development, regulatory and commercial milestones along with annual technology access fees post commercialisation. The FDA has granted orphan-drug designation to INBRX-101 for the treatment of AATD and an initial read-out from the ongoing registration-enabling trial is expected to occur in late 2024.
Sarah Howell, Chief Executive Officer of Arecor, said: "Following on from the recent commercialisation of AT220, which is now royalty-bearing for Arecor, the acquisition of Inhibrx for INBRX-101 by Sanofi, announced today, is a further endorsement of the Arestat(TM) platform. Sanofi is a global pharmaceutical leader with a 30-year heritage in rare diseases and this acquisition highlights both the value of this novel therapy for patients and its future commercial potential. We believe they are well placed to complete the late-stage development of this novel medicine and, ultimately, bring it to patients in need. We congratulate the Inhibrx team and look forward to working with Inhibrx and Sanofi, as well as updating the market on future developments from this programme."
INBRX-101 is an optimized recombinant human AAT-Fc fusion protein, for treatment of patients with emphysema due to AATD. AATD is an underdiagnosed inherited orphan genetic disease that can cause serious lung disease in adults and/or liver disease at any age, affecting an estimated 100,000 patients in the United States. INBRX-101 has the potential to significantly reduce the frequency of annual infusions, eliminate lung decline from Alpha-1 Disease, and could significantly improve patient quality of life compared to the current standard of care.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060 Officer Email: info@arecor.com Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060 Email: info@arecor.com Mo Noonan, Communications Tel: +44 (0) 7876 444977 Email: mo.noonan@arecor.com Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500 and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) ICR Consilium Chris Gardner, David Daley, Lindsey Tel: +44 (0) 20 3709 5700 Neville Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat(TM), we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat(TM) platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
UPDKZGZMVFVGDZM
(END) Dow Jones Newswires
January 23, 2024 11:58 ET (16:58 GMT)
1 Year Arecor Therapeutics Chart |
1 Month Arecor Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions